glp 1 growth hormone GLP-1 Semaglutide (GLP1) - Frontier Peptide

FDA Commissioner Marty Makary warned the offering and similar drugs were "illegal copycats." Novo followed up by suing the telehealth company for infringing patents on its injectable weight-loss offerings

DPP-4 inhibitors carry a minimal risk of hypoglycemia and gastrointestinal symptoms

The mechanisms of GLP-1RAs neuroprotection may be interconnected, warranting further investigation

The Remarkable Turnaround of the 1993-Born Chairman [Interview]" While global pharmaceutical companies are expanding the obesity drug market by focusing on mechanism-based competition, domestic pharmaceutical companies are seeking differentiation by improving formulation technology and administration methods

Bech, E